VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival.

Francesca FontanaMichael J ScottJohn S AllenXiaoxia YangGrace CuiDipanjan PanNoriko YanabaMark A FialaJulie O'NealAnne H Schmieder-AtteberryJulie RitcheyMichael RettigKathleen SimonsSteven FletcherRavi VijJohn F DiPersioGregory M Lanza

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

V-CP may be a safe and effective strategy to prevent or treat relapsing or refractory myeloma. V-NP targeting of resistant cells may suggest a new approach to environment-induced resistance in cancer.

Keyphrases

induced apoptosis
cell cycle arrest
cell adhesion
multiple sclerosis
cancer therapy
multiple myeloma
signaling pathway
squamous cell carcinoma
high glucose
rheumatoid arthritis
cell proliferation
endothelial cells
young adults
disease activity
drug induced
pi k akt
squamous cell
childhood cancer